Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults

James C. King, John Treanor, Patricia E. Fast, Mark Wolff, Lihan Yan, Dominic Iacuzio, Bernard Readmond, Diane O'Brien, Kenneth Mallon, W Edward Jr. Highsmith, John S. Lambert, Robert B. Belshe

Research output: Contribution to journalArticle

108 Citations (Scopus)

Abstract

Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1- 2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV- infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.

Original languageEnglish (US)
Pages (from-to)725-728
Number of pages4
JournalJournal of Infectious Diseases
Volume181
Issue number2
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Virus Shedding
Influenza Vaccines
Attenuated Vaccines
Vaccines
HIV
Viruses
Safety
Placebos
Nose
Centers for Disease Control and Prevention (U.S.)
CD4 Lymphocyte Count
Human Influenza
Immunization
Vaccination
RNA
Antibodies

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Immunology

Cite this

Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults. / King, James C.; Treanor, John; Fast, Patricia E.; Wolff, Mark; Yan, Lihan; Iacuzio, Dominic; Readmond, Bernard; O'Brien, Diane; Mallon, Kenneth; Highsmith, W Edward Jr.; Lambert, John S.; Belshe, Robert B.

In: Journal of Infectious Diseases, Vol. 181, No. 2, 2000, p. 725-728.

Research output: Contribution to journalArticle

King, James C. ; Treanor, John ; Fast, Patricia E. ; Wolff, Mark ; Yan, Lihan ; Iacuzio, Dominic ; Readmond, Bernard ; O'Brien, Diane ; Mallon, Kenneth ; Highsmith, W Edward Jr. ; Lambert, John S. ; Belshe, Robert B. / Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults. In: Journal of Infectious Diseases. 2000 ; Vol. 181, No. 2. pp. 725-728.
@article{46e1aabcb90741179318b2dadfeb6458,
title = "Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults",
abstract = "Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1- 2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV- infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.",
author = "King, {James C.} and John Treanor and Fast, {Patricia E.} and Mark Wolff and Lihan Yan and Dominic Iacuzio and Bernard Readmond and Diane O'Brien and Kenneth Mallon and Highsmith, {W Edward Jr.} and Lambert, {John S.} and Belshe, {Robert B.}",
year = "2000",
doi = "10.1086/315246",
language = "English (US)",
volume = "181",
pages = "725--728",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "2",

}

TY - JOUR

T1 - Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV- infected adults

AU - King, James C.

AU - Treanor, John

AU - Fast, Patricia E.

AU - Wolff, Mark

AU - Yan, Lihan

AU - Iacuzio, Dominic

AU - Readmond, Bernard

AU - O'Brien, Diane

AU - Mallon, Kenneth

AU - Highsmith, W Edward Jr.

AU - Lambert, John S.

AU - Belshe, Robert B.

PY - 2000

Y1 - 2000

N2 - Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1- 2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV- infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.

AB - Fifty-seven human immunodeficiency virus (HIV)-infected (CDC class A1- 2) and 54 non-HIV-infected adults, not prescreened for influenza susceptibility, were randomized to receive trivalent live attenuated influenza vaccine (LAIV) or placebo intranasally. LAIV was safe and well tolerated with no serious adverse events attributable to vaccine. Reactogenicity rates were similar in LAIV and placebo recipients except that runny nose/nasal congestion was significantly more common in LAIV recipients regardless of HIV status. No prolonged shedding of LAIV was observed in HIV- infected participants. HIV RNA levels were not increased and CD4 counts were not decreased in HIV-infected LAIV recipients compared with placebo recipients after immunization. Shedding of LAIV and increases in antibody titers were infrequent, consistent with prior experience in unscreened adults. The data suggest that inadvertent vaccination with LAIV in relatively asymptomatic HIV-infected adults would not be associated with frequent significant adverse events.

UR - http://www.scopus.com/inward/record.url?scp=0034051823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034051823&partnerID=8YFLogxK

U2 - 10.1086/315246

DO - 10.1086/315246

M3 - Article

C2 - 10669363

AN - SCOPUS:0034051823

VL - 181

SP - 725

EP - 728

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 2

ER -